High Dose Ascorbic Acid Treatment of CMT1A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00484510

Recruitment Status : Completed

First Posted : June 11, 2007

Last Update Posted : March 6, 2013

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Muscular Dystrophy Association

Charcot-Marie-Tooth Association

Information provided by (Responsible Party):

Michael E. Shy, MD, Wayne State University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	December 2012
Actual Study Completion Date :	December 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME; Muscle Study Group. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013 Aug;70(8):981-7. doi: 10.1001/jamaneurol.2013.3178.

To Top